Briumvi Breakthrough: TG Therapeutics Pops on Promising MS Shot Data

TG Therapeutics (NASDAQ: TGTX) is trading higher after fresh clinical data supported a more convenient, under‑the‑skin version of its multiple sclerosis therapy Briumvi (ublituximab‑xiiy), reinforcing the company’s push to make treatment easier for patients and more efficient for infusion centers.

What TG Therapeutics is developing

TG Therapeutics is working on a subcutaneous (under‑the‑skin) formulation of Briumvi for people with relapsing forms of multiple sclerosis, designed so patients could receive injections at home every two or three months instead of going into a clinic for an intravenous infusion every six months. This new version aims to match the effectiveness and safety of the approved IV drug while offering a more flexible, patient‑friendly dosing schedule.

In parallel, the company reported positive Phase 3 ENHANCE data for Briumvi, showing that a streamlined single 600 mg IV infusion on Day 1 delivered bioequivalent drug exposure to the current two‑step initiation regimen (150 mg on Day 1 plus 450 mg on Day 15). Safety and tolerability in ENHANCE were consistent with Briumvi established profile, which already includes known risks such as infusion reactions and infections.

Why the new data matters

From a medical and commercial standpoint, the results suggest TG Therapeutics may soon be able to offer both:

• A simpler IV start (one infusion instead of two in the first 15 days).
• A potentially at‑home, subcutaneous option that could reduce travel and time in infusion chairs.

The company plans to file a supplemental biologics license application (sBLA) in the second half of 2026 to seek approval for the single‑infusion IV initiation regimen. Meanwhile, the Phase 3 subcutaneous trial has finished enrollment and is comparing at‑home injections given every 8 or 12 weeks with the standard IV schedule, with top‑line data expected around late 2026 or early 2027.

What this could mean for investors

If regulators agree that the single‑infusion IV start is equivalent, TG Therapeutics could remove a clinic visit from the initiation phase, which may help infusion centers manage capacity and make Briumvi more convenient to start. Looking ahead, a successful subcutaneous program could further differentiate Briumvi in a competitive MS market by giving patients and providers more flexibility—similar to how other autoimmune drugs gained share when at‑home options became available.